DOR BioPharma Receives Notice of Delisting from American Stock Exchange; Company to Continue to Negotiate Potential Compliance-A

DOR BioPharma, Inc. (AMEX: DOR) ("DOR" or the
"Company"), announced today that it has received notice from the
American Stock Exchange (the "AMEX") indicating that it no longer
complies with the AMEX's continued listing standards and that it
intends to proceed with removal of the Company's common stock from
listing and registration on the AMEX. The AMEX has permitted the
Company's common stock to be listed pursuant to a plan period, which
expired on October 15, 2005. AMEX determined that the Company was not
in compliance with the requirement that it maintain more than $6
million of stockholders' equity as it has sustained losses from
continuing operations and/or net losses in three of its four most
recent fiscal years.
   DOR has been afforded an opportunity to appeal the decision and to
present its reasons in support of continued listing, and it is
expected to do so shortly. DOR will pay a hearing fee and have a
hearing scheduled. Such hearings are usually held within 45 days after
the request is made. Pending the resolution of the appeal, the stock
will continue to be listed on the American Stock Exchange. A request
for a hearing will ordinarily stay a delisting action, though the AMEX
may immediately suspend trading pending its review if it is determined
to be in the public interest. There can be no assurance that the
Company's request for continued listing will be granted.
   In the event that the Company's common stock is ever delisted from
the AMEX, the Company expects that its shares will be eligible for
quotation on the OTC Bulletin Board electronic market. The Company
believes that this would still allow shareholders an adequate
opportunity to trade their common shares in the future.
   Michael T. Sember, President and Chief Executive Officer of DOR
commented, "Despite being out of compliance with the continued listing
requirements of the AMEX for much of the year, 2005 has been a good
year for DOR BioPharma and its programs. We are in contact with the
AMEX and are working diligently to regain compliance with the AMEX
listing standards. Some of the concrete steps that we are taking to
build shareholder value will become apparent in the immediate future."

   About DOR BioPharma, Inc.

   DOR BioPharma, Inc. is a biopharmaceutical company focused on the
development of therapeutic products and biomedical countermeasures for
areas of unmet medical need. Our lead product, orBec(R) (oral
beclomethasone dipropionate), is a potent, locally-acting
corticosteroid being developed for the treatment of intestinal
Graft-versus-Host disease (iGVHD), a common serious complication of
bone marrow transplantation for cancer, as well as other
gastrointestinal disorders characterized by severe inflammation. We
plan to file a new drug application (NDA) with the FDA for orBec(R)
for the treatment of intestinal iGVHD later this year or early next
quarter.
   Through our BioDefense Division, we are developing biomedical
countermeasures pursuant to the paradigm established by the recently
enacted Project BioShield Act of 2004. Our biodefense products in
development are bioengineered vaccines designed to protect against the
deadly effects of ricin toxin and botulinum toxin, both of which are
considered serious bioterrorism threats. Our ricin toxin vaccine,
RiVaxTM, has completed the clinical portion of its Phase I clinical
trial in normal volunteers. We have also announced the initiation of a
new botulinum toxin therapeutic development program based on rational
drug design.
   For further information regarding DOR BioPharma, please visit the
Company's website located at http://www.dorbiopharma.com.
   This press release contains forward-looking statements, within the
meaning of Section 21E of the Securities Exchange Act of 1934, that
reflect DOR BioPharma's current expectations about its future results,
performance, prospects and opportunities, including statements
regarding the potential use of orBec(R) for the treatment of iGVHD and
the prospects for regulatory filings for orBec(R). Where possible, DOR
BioPharma has tried to identify these forward-looking statements by
using words such as "anticipates", "believes", "intends", or similar
expressions. These statements are subject to a number of risks,
uncertainties and other factors that could cause actual events or
results in future periods to differ materially from what is expressed
in, or implied by, these statements. DOR BioPharma cannot assure you
that it will be able to successfully develop or commercialize products
based on its technology, including orBec(R), particularly in light of
the significant uncertainty inherent in developing vaccines against
bioterror threats, manufacturing and conducting preclinical and
clinical trials of vaccines, and obtaining regulatory approvals, that
its technologies will prove to be safe and effective, that its cash
expenditures will not exceed projected levels, that it will be able to
obtain future financing or funds when needed, that product development
and commercialization efforts will not be reduced or discontinued due
to difficulties or delays in clinical trials or due to lack of
progress or positive results from research and development efforts,
that it will be able to successfully obtain any further grants and
awards, maintain its existing grants which are subject to performance,
enter into any biodefense procurement contracts with the U.S.
Government or other countries, that it will be able to patent,
register or protect its technology from challenge and products from
competition or maintain or expand its license agreements with its
current licensors, or that its business strategy will be successful.
Important factors which may affect the future use of orBec(R) for
iGVHD include the risks that: because orBec(R) did not achieve
statistical significance in its primary endpoint in the pivotal Phase
III clinical study (i.e. a p-value of less than or equal to 0.05), the
FDA may not consider orBec(R) approvable based upon existing studies,
orBec(R) may not show therapeutic effect or an acceptable safety
profile in future clinical trials, if required, or could take a
significantly longer time to gain regulatory approval than DOR
BioPharma expects or may never gain approval; Dor BioPharma is
dependent on the expertise, effort, priorities and contractual
obligations of third parties in the clinical trials, manufacturing,
marketing, sales and distribution of its products; or orBec(R) may not
gain market acceptance; and others may develop technologies or
products superior to orBec(R). Dor BioPharma's business strategy has
been revised to include the issuance of its securities to acquire
companies or assets. Dor BioPharma presently is involved in
negotiations which could result in the issuance of a significant
number of shares of its equity securities, thereby diluting the equity
interests of present stockholders. These and other factors are
described from time to time in filings with the Securities and
Exchange Commission, including, but not limited to, DOR BioPharma's
most recent reports on Form 10-QSB and Form 10-KSB. DOR BioPharma
assumes no obligation to update or revise any forward-looking
statements as a result of new information, future events, and changes
in circumstances or for any other reason.